<DOC>
	<DOCNO>NCT01570361</DOCNO>
	<brief_summary>The objective study determine whether early radiofrequency ( RF ) ablation treatment , use CARTO® 3 CARTO® XP System , THERMOCOOL® Catheter Family ( include THERMOCOOL® SF THERMOCOOL® SMARTTOUCH™ ) subject paroxysmal atrial fibrillation ( PAF ) , delay progression atrial fibrillation ( AF ) compare drug therapy ( either rate rhythm control ) use current AF management guideline .</brief_summary>
	<brief_title>Atrial Fibrillation Progression Trial</brief_title>
	<detailed_description>Eligible PAF subject recurrent AF 2 year fail 2 prescribed drug ( either anti-arrhythmic rate control drug ) randomize one two study arm ( catheter ablation drug therapy ) .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>1 . Patients recurrent paroxysmal atrial fibrillation ( AF ) least 2 year , ≥ 2 episode last 6 month ; ( per Amendment v3 , 09APR2013 , previous `` 6 episode '' ) 2 . HATCH Score least ≥1 ≤4 . 3 . Eligible catheter ablation antiarrhythmic rate control medication , fail least 1 2 prescribe drug ( either antiarrhythmic rate control drug ) . 4 . Age 60 year old . 5 . Left atrium ( LA ) diameter ≤ 55mm TTE . 6 . Left ventricle ( LV ) ejection fraction ≥50 % sinus rhythm LV ejection fraction ≥35 % atrial fibrillation . NOTE : For patient enter study AF ejection fraction ≥35 % &lt; 50 % ; ejection fraction rechecked sinus rhythm . In case ejection fraction &gt; 50 % subject continue study . 7 . Patient sign Informed Consent Form able willing comply protocol requirement , include baseline followup test . 1 . Patients await cardiac transplantation cardiac surgery . 2 . Acute illness ( ongoing ) active systemic infection sepsis opinion investigator , may adversely affect safety and/or effectiveness participant study . 3 . Reversible cause atrial fibrillation , e.g . limited thyroid disorder , acute alcohol intoxication , recent major surgical procedure trauma , etc . 4 . Recent cardiac event include myocardial infarction ( MI ) , percutaneous coronary intervention ( PCI ) , valve bypass surgery precede 3 month . 5 . Heart failure decompensation . 6 . Previously diagnose persistent/permanent atrial fibrillation/ atrial flutter . 7 . Previously require cardioversion &gt; 48 hour onset atrial fibrillation/ atrial flutter . 8 . Subject previous transischemic attack ( TIA ) stroke ( cerebrovascular accident ) one year prior patient enrolment and/or sufficient recovery . 9 . Pulmonary embolism recent atrial embolism/thrombosis . 10 . Hypertrophic obstructive cardiomyopathy . 11 . Class IV angina Class IV congestive heart failure ( CHF ) ( include past plan heart transplantation ) . 12 . Mandated antiarrhythmic drug therapy disease condition atrial fibrillation . 13 . Heritable arrhythmia increase risk torsade de pointes class I III Drugs . 14 . Prior leave atrial catheter ablation intention treat atrial fibrillation ; prior surgical intervention AF MAZE procedure . 15 . Prior AV nodal ablation . 16 . Patients present contraindication study catheter ( ) , indicate respective Instructions For Use . 17 . Contraindication warfarin , anticoagulation therapy , antiplatelet medication . 18 . Medical condition limit expect survival &lt; 3 year . 19 . Concurrent participation clinical study . 20 . Prior history nonadherence prescribe drug regimen . 21 . Women child bear potential pregnant , lactate , plan become pregnant course trial NOTE : Prior ablation cavotricuspid isthmus reason exclude , patient develops subsequent recurrent atrial fibrillation . NOTE : For patient randomized PVI group ( Test Group ) , Transesophageal Echocardiography ( TEE ) perform ( per standard care ) , within 48 hour preprocedure , exclude atrial thrombus structural contraindication ablation procedure .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>Arrhythmias , Cardiac</keyword>
	<keyword>Heart Diseases</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Pathologic Processes</keyword>
</DOC>